<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02436889</url>
  </required_header>
  <id_info>
    <org_study_id>14-15553</org_study_id>
    <nct_id>NCT02436889</nct_id>
  </id_info>
  <brief_title>Treatment of Incontinence Without Memory Problems</brief_title>
  <acronym>TRIUMPH</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An 8-week randomized, controlled, pilot clinical trial of Mirabegron compared to a standard
      anticholinergic therapy (Detrol LA) in elderly women with urgency urinary incontinence.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility - Assessment of Recruitment and Retention Rates</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive performance will be measured by standardized neuropsychologic tests</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical function/mobility will be measured with Short Physical Performance Battery (SPPB)</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Incontinence frequency measured by a voiding diary</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Urge Incontinence</condition>
  <condition>Urinary Incontinence, Urge</condition>
  <arm_group>
    <arm_group_label>Mirabegron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolterodine Tartrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <arm_group_label>Mirabegron</arm_group_label>
    <other_name>Myrbetriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine Tartrate</intervention_name>
    <arm_group_label>Tolterodine Tartrate</arm_group_label>
    <other_name>Detrol LA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Community-dwelling, ambulatory females ≥ 65 years old

          -  Urgency or Mixed Urgency Predominate Urinary Incontinence (subject-reported) for ≥ 3
             months prior to Screening (Visit 1)

          -  On a 3-day voiding diary, documentation of at least 3 urgency incontinence episodes
             with the number of urgency incontinence episodes greater than number of stress
             incontinence episodes

          -  Capability of understanding and having signed the informed consent form after full
             discussion of the research nature of the treatment and its risk and benefits

          -  Ability to perform all procedures and tests required by the protocol

          -  Report having a primary health care provider

          -  Willingness to remain on stable medication regime for duration of the randomized
             controlled trial. Participants will be asked to not add new medications during the
             randomized controlled trial, such as diuretics and other medications which may affect
             their voiding pattern.

        Exclusion Criteria:

          -  Seated blood pressure &gt;180/110 at Screening or Baseline

          -  Physician diagnosis of dementia

          -  Current use of dementia medications, debilitating or recent neurologic disease

          -  Mini Mental State Examination (MMSE) score &lt;20

          -  History of urinary retention, gastric retention, uncontrolled narrow angle glaucoma,
             myasthenia gravis, severe ulcerative colitis, toxic megacolon, fistula or a hole in
             your bladder or rectum, birth defect leading to urine leakage, and urine leakage
             starting in childhood

          -  Clinically significant hepatic (Child Pugh B or greater) or renal (creatinin clearance
             &lt;30 mL/min or eGFR &lt;30 mL/min/1.73 m2)

          -  Neurologic conditions such as stroke, multiple sclerosis, spinal cord injury, or
             Parkinson's disease.

          -  Major cardiovascular even in the past 6 months (i.e., MI, unstable angina,
             hospitalization for chest pain)

          -  Symptomatic pelvic organ prolapse defined as participant report of feeling or seeing a
             bulge outside the vagina within the past 3 months.

          -  History of surgery for incontinence in the past 5 years, pelvic surgery the past 6
             months (i.e., for prolapse or hysterectomy), intra-vesical therapy (botox), and/or
             bulk injections within the past 6 months.

          -  A known history of interstitial cystitis or a significant pain component associated
             with OAB symptoms, uninvestigated hematuria, urogenital cancer, radiation to the
             pelvis or external genitalia.

          -  Urinary tract infection (UTI) as shown by the results of the urinalysis at screening
             or recurrent urinary tract infection (RUTIs) defined as treatment for UTI &gt;3 times in
             the last year.

          -  Urinary retention (post-void residual urine volume &gt;150 cc measured by Bladder scan at
             screening.

          -  Use of any electrostimulation, bladder training, or pelvic floor exercises (with
             certified incontinence practitioners) within 4 weeks of Screening.

          -  Received study medication in any previous mirabegron clinical trial.

          -  Prior failure for either efficacy or tolerability of ≥ 2 OAB medications in the last
             year. (Failure: inadequate symptom control after two medications for a minimum of one
             month each.)

          -  Has been treated within 2 weeks prior to Screening and/or is currently being treated
             with:

               -  Any drug treatment for OAB

               -  Any drugs with significant anticholinergic and antispasmodic effects (see
                  exception for tricyclic antidepressants below)

          -  Has started treatment with tricyclic antidepressants or estrogens within 4 weeks prior
             to Screening and/or is not on a stable dose.

          -  Intermittent use or unstable dose of diuretics. Treatment with diuretics initiated
             within 2 weeks prior to baseline and/or is not on a stable dose is not permitted.

          -  Treatment with potent CYP3A4 inhibitors, such as clarithromycin, ketoconazole, and
             itraconazole within 2 weeks prior to Screening.

          -  Administration of medications capable of inducing hepatic enzyme metabolism or
             transport (e.g., barbiturates, rifampicin, carbamazepine, phenytoin, primidone, or St.
             John's Wort) in the past 30 days.

          -  Administration of narrow therapeutic index drugs metabolized by CYP2D6, such as
             thioridazine, flecainide, and propafenone.

          -  Previously received any investigational drug within 30 days prior to trial entry.

          -  Alcohol and/or any other drug abuse in the opinion of the investigator.

          -  Participants who have any medical (including known history of major hematological,
             renal, cardiovascular, or hepatic abnormalities) or psychological condition or social
             circumstances that would impair their ability to participate reliably in the trial, or
             those who may increase the risk to themselves or others by participating.

          -  Participants who, in the opinion of the investigator, are not likely to complete the
             trial for whatever reason.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslee Subak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Leslee Subak</investigator_full_name>
    <investigator_title>Professor of Ob/Gyn &amp; Reproductive Sciences; Epidemiology &amp; Biostatistics; Urology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
    <mesh_term>Tolterodine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

